For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

E. R. Squibb Sons, Inc.

USPTO Granted Patents = 1,624

CIPO Patents = 161

EPO Patents = 27

Trademarks = 125

Forward Citations = 23,760

Loading Chart...

Loading Chart...

653 inventors (with patents filed for the assignee):

Miguel A Ondetti (100 out of 100 patents)

Eric M Gordon (85 out of 100 patents)

Uwe D Treuner (79 out of 82 patents)

4. Hans Hoehn (78 out of 78 patents)

5. Hermann Breuer (74 out of 75 patents)

6. John Krapcho (66 out of 66 patents)

7. Ravi K Varma (62 out of 62 patents)

8. Christopher M Cimarusti (55 out of 55 patents)

9. Peter C Wade (54 out of 54 patents)

10. B Richard Vogt (54 out of 54 patents)

11. Frederic P Hauck (54 out of 54 patents)

12. Theodor Denzel (53 out of 53 patents)

13. Donald S Karanewsky (50 out of 61 patents)

14. Joseph E Sundeen (46 out of 55 patents)

15. Martin F Haslanger (45 out of 52 patents)

Core Competencies:

Cation Exchange Chromatography

Human Antibodies

Lymphocyte Activation Gene-3

Interferon Receptor 1

Monoclonal Antibodies

Programmed Death 1

Transgenic Rodents

Therapeutic Antibodies

Anti-PD-1 Antibodies

Fucosyl-GM1 Antibodies

Protein Tyrosine Kinase 7

Chimeric Antibodies

1,624 patents: Sort by Forward Citations

1. 12157757 - Cation exchange chromatography methods (2024-12-03),

2. 11530267 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-12-20),

3. 11512130 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-11-29),

4. 11384363 - HCO32 and HCO27 and related examples (2022-07-12),

5. 11292814 - Cation exchange chromatography methods (2022-04-05),

6. 11236165 - Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof (2022-02-01),

7. 11236164 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-02-01),

8. 11236163 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-02-01),

9. 11072664 - Interferon receptor 1 antibodies and their uses (2021-07-27),

10. 11001630 - Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof (2021-05-11),

11. 10988536 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2021-04-27),

12. 10988535 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2021-04-27),

13. 10501556 - Compositions and methods for treating cocaine-related disorders (2019-12-10),

14. 10448622 - Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission (2019-10-22),

15. 10441655 - Monoclonal antibodies to programmed death 1 (PD-1) (2019-10-15),

E. R. Squibb Sons, Inc. is a pharmaceutical company known for its commitment to innovation and quality in the development of medicines. Founded in the 19th century, the company has a rich history of scientific advancement and has contributed significantly to the healthcare industry. E. R. Squibb Sons, Inc. focuses on research and development, producing a range of pharmaceutical products that address various medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

1,624 Patents

#2 in Princeton, NJ

#20 in New Jersey

#304 in US

#600 in the World

Princeton, NJ, United States of America

E. R. Squibb Sons, Inc.

Forward Citations = 23,760

653 inventors:

Miguel A Ondetti (100 out of 100 patents)

Eric M Gordon (85 out of 100 patents)

Uwe D Treuner (79 out of 82 patents)

4. Hans Hoehn (78 out of 78 patents)

5. Hermann Breuer (74 out of 75 patents)

Please report any incorrect information to support@idiyas.com

Loading…